Glargine-300: An updated literature review on randomized controlled trials and real-world studies

Despite the availability of a variety of insulins,rates of insulinisation and the acceptance of insulin therapy is suboptimal in real-world clinical settings.Patient and physician concerns with hypoglycaemia and weight gain are the two key issues that serve to impede appropriate insulinisation in patients with diabetes.Recently introduced second-generation basal insulin analogues [for e.g.,insulin glargine 300 U/m L(Gla-300) and insulin degludec] are designed to have improved pharmacokinetic profiles with an intention to deliver steady insulin levels over a longer period.Several randomised controlled and real-world studies have proven the resultant advantages of second-generations insulin analogues in lowering intra-individual variability in plasma insulin levels,flexibility in dosing,a sustained glucose-lowering effect,and decreasing the risk of hypoglycaemia.Gla-300 is one of the newer second-generation basal insulin analogues to have been approved for both type 1 and 2 diabetes.In this article,we review the currently available clinical and real-world data of Gla-300.